CA2858984C - Use of c1-inhibitor for the treatment of secondary edema of the central nervous system - Google Patents

Use of c1-inhibitor for the treatment of secondary edema of the central nervous system Download PDF

Info

Publication number
CA2858984C
CA2858984C CA2858984A CA2858984A CA2858984C CA 2858984 C CA2858984 C CA 2858984C CA 2858984 A CA2858984 A CA 2858984A CA 2858984 A CA2858984 A CA 2858984A CA 2858984 C CA2858984 C CA 2858984C
Authority
CA
Canada
Prior art keywords
inhibitor
edema
brain
use according
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2858984A
Other languages
English (en)
French (fr)
Other versions
CA2858984A1 (en
Inventor
Christoph Kleinschnitz
Marc Nolte
Guido Stoll
Gerhard Dickneite
Stefan Schulte
Bernhard Nieswandt
Ingo Pragst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CA2858984A1 publication Critical patent/CA2858984A1/en
Application granted granted Critical
Publication of CA2858984C publication Critical patent/CA2858984C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2858984A 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system Active CA2858984C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11195254 2011-12-22
EP11195254.5 2011-12-22
US201261587371P 2012-01-17 2012-01-17
US61/587,371 2012-01-17
PCT/EP2012/076691 WO2013093027A1 (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Publications (2)

Publication Number Publication Date
CA2858984A1 CA2858984A1 (en) 2013-06-27
CA2858984C true CA2858984C (en) 2021-01-05

Family

ID=48667767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2858984A Active CA2858984C (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Country Status (10)

Country Link
US (1) US9452203B2 (cg-RX-API-DMAC7.html)
EP (1) EP2793935B1 (cg-RX-API-DMAC7.html)
JP (1) JP6127063B2 (cg-RX-API-DMAC7.html)
KR (1) KR102022231B1 (cg-RX-API-DMAC7.html)
CN (1) CN104080474B (cg-RX-API-DMAC7.html)
AU (1) AU2012318275B2 (cg-RX-API-DMAC7.html)
CA (1) CA2858984C (cg-RX-API-DMAC7.html)
DK (1) DK2793935T3 (cg-RX-API-DMAC7.html)
ES (1) ES2587863T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013093027A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
LT3290046T (lt) 2013-03-15 2019-03-12 Shire Viropharma Incorporated C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
JP3941174B2 (ja) 1996-08-26 2007-07-04 富士ゼロックス株式会社 複合材料及びその製造方法
EP1216052A1 (en) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
KR101508668B1 (ko) 2005-12-21 2015-04-06 파밍 인텔렉츄얼 프라퍼티 비.브이. 허혈-재관류 손상의 예방을 위한 ｃ１ 억제제의 용도
ES2654816T3 (es) * 2005-12-21 2018-02-15 Pharming Intellectual Property B.V. Uso del inhibidor C1 para la prevención de lesión de reperfusión de isquemia

Also Published As

Publication number Publication date
EP2793935A1 (en) 2014-10-29
HK1201729A1 (zh) 2015-09-11
AU2012318275A1 (en) 2013-07-11
CN104080474A (zh) 2014-10-01
KR20140107567A (ko) 2014-09-04
ES2587863T3 (es) 2016-10-27
US20140371425A1 (en) 2014-12-18
JP6127063B2 (ja) 2017-05-10
DK2793935T3 (en) 2016-09-05
JP2015502389A (ja) 2015-01-22
EP2793935B1 (en) 2016-05-25
KR102022231B1 (ko) 2019-09-19
AU2012318275B2 (en) 2016-05-19
WO2013093027A1 (en) 2013-06-27
CA2858984A1 (en) 2013-06-27
US9452203B2 (en) 2016-09-27
CN104080474B (zh) 2016-04-27

Similar Documents

Publication Publication Date Title
CA2858984C (en) Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
Göb et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation
Kraft et al. The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood–brain-barrier damage, inflammation and thrombosis
KR101956585B1 (ko) 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
Mencl et al. FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation
KR20130054953A (ko) 간질성 폐 질환을 치료하기 위한 인자 ｘｉｉ 억제제
JP2015509984A (ja) 子癇前症の治療におけるアンチトロンビンの使用
KR20170016503A (ko) 신경외상성 장애에서의 인자 xii 억제제를 이용한 치료요법
HK1201729B (en) Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
Cirak et al. The effects of endothelin antagonist BQ-610 on cerebral vascular wall following experimental subarachnoid hemorrhage and cerebral vasospasm
US7375076B2 (en) Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
Cao et al. Anti-Angiogenic and Anti-Scarring Dual Effect of Galectin-3 Inhibition in Mouse Models of Corneal Wound Healing
US20250144179A1 (en) Peptide hormone to prevent or treat vasospasm, brain injury or cerebral edema
Tamanna et al. ACE2: A key modulator of RAS and pregnancy
US10441631B2 (en) Therapeutic agent for amniotic fluid embolism
Shanmugaiah et al. The efficacy of intracisternal irrigation of papaverine on cerebral blood flow in patients with subarachnoid hemorrhage
Elkhrbash The role of angiotensin AT1 and AT2 receptors in the development of apoptosis and inflammation following experimental myocardial infarction
Jin et al. Amelioration of Post‐Stroke Edema and Microcirculatory Dysfunction via Targeted AQP4 Inhibition While Preserving the Glymphatic System
US20200062855A1 (en) Compositions and methods of promoting wound healing
Song et al. Up-regulation of TGF-β via the activation of extracellular signal-regulated kinase 1 and 2 induced by prorenin in human renal mesangial cells
S Hernandes et al. Hernandes et al., 2018. pdf
Revill et al. Ecallantide
US20130053546A1 (en) Use of Anticoagulants in the Production of Recombinant Proteins in the Milk of Transgenic Animals
Kwon et al. AT1 receptor blocker losartan protects against 1 mechanical ventilation-induced diaphragmatic dysfunction 2 3 4 5
Kwon et al. AT1 receptor blocker losartan protects against 1 mechanical ventilation-induced diaphragmatic dysfunction 2 3 4 Revision# 2 August 31, 2015 5

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171116